🩸 Can ctDNA capture response before surgery in MIBC?

OncoDaily IO· @OncoDailyIO · X·2026-10-23 23:11· 2 days agoScore70

Body

🩸 Can ctDNA capture response before surgery in MIBC?
https://oncodaily.com/oncolibrary/immune-oncology/keynote-b15-ctdna

Exploratory KEYNOTE-B15/EV-304 analysis:
ctDNA clearance: 82.1% with EV + pembrolizumab vs 66.7% with gemcitabine–cisplatin.
Clearance was associated with better EFS.

#ESMO2026 #OncoDaily #ESMO26 #KEYNOTEB15

120 views · 1 like · 1 repost · 0 replies

Conference abstracts

4734Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

https://esmocongress.esmo.org

NCT04700124NCT04700124matched by - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

https://esmocongress.esmo.org

Source: OncoDaily IO · x.com